- Home
- RPRX vs XPEV Comparison
RPRX vs XPEV Comparison
Compare RPRX & XPEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- XPEV
- Stock Information
- Founded
- RPRX 1996
- XPEV 2015
- Country
- RPRX United States
- XPEV China
- Employees
- RPRX N/A
- XPEV N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- XPEV Auto Manufacturing
- Sector
- RPRX Health Care
- XPEV Consumer Discretionary
- Exchange
- RPRX Nasdaq
- XPEV Nasdaq
- Market Cap
- RPRX 16.2B
- XPEV 21.7B
- IPO Year
- RPRX 2020
- XPEV 2020
- Fundamental
- Price
- RPRX $39.54
- XPEV $26.54
- Analyst Decision
- RPRX Strong Buy
- XPEV Buy
- Analyst Count
- RPRX 3
- XPEV 8
- Target Price
- RPRX $46.00
- XPEV $22.51
- AVG Volume (30 Days)
- RPRX 3.7M
- XPEV 14.4M
- Earning Date
- RPRX 11-05-2025
- XPEV 11-17-2025
- Dividend Yield
- RPRX 2.21%
- XPEV N/A
- EPS Growth
- RPRX N/A
- XPEV N/A
- EPS
- RPRX 1.75
- XPEV N/A
- Revenue
- RPRX $2,349,844,000.00
- XPEV $8,416,181,216.00
- Revenue This Year
- RPRX $36.16
- XPEV $99.25
- Revenue Next Year
- RPRX $2.04
- XPEV $39.50
- P/E Ratio
- RPRX $22.68
- XPEV N/A
- Revenue Growth
- RPRX 3.70
- XPEV 66.37
- 52 Week Low
- RPRX $24.05
- XPEV $11.14
- 52 Week High
- RPRX $41.24
- XPEV $28.24
- Technical
- Relative Strength Index (RSI)
- RPRX 61.44
- XPEV 61.77
- Support Level
- RPRX $38.39
- XPEV $21.60
- Resistance Level
- RPRX $41.24
- XPEV $28.20
- Average True Range (ATR)
- RPRX 1.23
- XPEV 1.30
- MACD
- RPRX 0.15
- XPEV 0.48
- Stochastic Oscillator
- RPRX 67.51
- XPEV 75.02
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About XPEV XPeng Inc.
Founded in 2015, XPeng is a leading Chinese smart electric vehicle company that designs, develops, manufactures, and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 190,000 EVs in 2024, accounting for about 2% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.